Therapy of Helicobacter pylori

Helicobacter

Volumn 9, Issue SUPPL. 1, 2004, Pages 42-48

  McLoughlin, Ramona ^a   Racz, Istvan ^b   Buckley, Martin ^a   O'Connor, Humphrey J ^a   O'Morain, Colm ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b Endocrinology and Diabetology   (Hungary)

Author keywords

Antibiotics; H. pylori; Resistance; Review; Treatment

Indexed keywords

12 SULFODEHYDROABIETIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BISMUTH; CLARITHROMYCIN; ESSENTIAL OIL; FURAZOLIDONE; GINGEROL; HISTAMINE H2 RECEPTOR ANTAGONIST; INTERLEUKIN 8; LACTOFERRICIN; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROPOLIS; PROTON PUMP INHIBITOR; RANITIDINE; RANITIDINE BISMUTH CITRATE; REBAMIPIDE; RIFABUTIN; STOMACH SECRETION INHIBITOR; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC SENSITIVITY; CLINICAL TRIAL; CYMBOPOGON CITRATUS; DIZZINESS; DRUG DOSE REGIMEN; ERADICATION THERAPY; FATIGUE; FEVER; GINGER; HELICOBACTER INFECTION; HUMAN; IN VITRO STUDY; INFECTION RESISTANCE; LACTOBACILLUS JOHNSONII; LIPPIA; NONHUMAN; PATIENT COMPLIANCE; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; ROOT VEGETABLE; SMOKING CESSATION; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PATIENT COMPLIANCE; TREATMENT OUTCOME;

CYMBOPOGON; CYMBOPOGON CITRATUS; HELICOBACTER; HELICOBACTER PYLORI; LACTOBACILLUS; LACTOBACILLUS JOHNSONII; LIPPIA; PROPOLIS; ZINGIBER OFFICINALE;

EID: 4644280540     PISSN: 10834389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1083-4389.2004.00251.x     Document Type: Review

References (40)

1. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:-167-80.
2. Wheeldon TU, Hoang TT, Phung DC, Bjorkman A, Granstrom M, Sorberg M. Helicobacter pylori eradication and peptic ulcer healing. the impact of deleting the proton pump inhibitor and using a once-daily treatment. Aliment Pharmacol Ther 2003;18:93-100.
3. Uthaisaengsook W. Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection. J Med Assoc Thai 2003;86:599-602.
4. de Boer SY, vd Meeberg PC, Siem H, de Boer WA. Comparison of four-day and seven-day pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection. Neth J Med 2003;61:218-22.
5. Lara LF, Cisneros G, Gurney M, et al. One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection. Arch Intern Med 2003;163:2079-84.
6. Veldhuyzen van Zanten S, Chiba N, Barkun A, et al. A randomized trial comparing seven-day ranitidine bismuth citrate and clarithromycin dual therapy to seven-day omeprazole, clarithromycin and amoxicillin triple therapy for the eradication of Helicobacter pylori. Can J Gastroenterol 2003; 17:533-8.
7. Romero-Gomez M, Martinez-Delgado C, Hergueta P, et al. Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcer. Aliment Pharmacol Ther 2003;18:1023-9.
8. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17:719-26.
9. Hassan C, De Francesco V, Zullo A, Scaccianoce G, Piglionica D, Ierardi E, Panella C, Morini S. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Aliment Pharmacol Ther 2003;18:641-6.
10. Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy - results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003;17:99-109.
11. De Francesco V, Zullo A, Margiotta M, et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther 2004;19:407-14.
12. Gisbert JP, Khorrami S, Calvet X, Gabriel R, Carballo F, Pajares JM. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists - their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;18:757-66.
13. Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003; 18:647-54.
14. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:1333-43.
15. Hiyama T, Tanaka S, Masuda H, et al. Prevalence of Helicobacter pylori resistance to clarithromycin and metronidazole determined by 23S ribosomal RNA and rdxA gene analyses in Hiroshima, Japan. J Gastroenterol Hepatol 2003;18:1202-7.
16. Crone J, Granditsch G, Huber WD, et al. Helicobacter pylori in children and adolescents: increase of primary clarithromycin resistance, 1997-2000. J Pediatr Gastroenterol Nutr 2003;36:368-71.
17. McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003;139:463-9.
18. Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, Kagawa J. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 2003;17:119-23.
19. Neri M, Milano A, Laterza F, Di Bonaventura G, Piccolomini R, Caldarella MP, Balatsinou C, Lapenna D, Cuccurullo F. Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Aliment Pharmacol Ther 2003;18:821-7.
20. Romano M, Marmo R, Cuomo A, et al. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2003;1:273-8.
21. Qasim A, Sebastian S, Buckley M, O'Connor H, O'Morain C. Pretreatment Antimicrobial susceptibility testing is not cost saving in the standard eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2004;2:85.
22. Miwa H, Nagahara A, Kurosawa A, et al. Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther 2003;17: 1545-51.
23. Lamouliatte H, Megraud F, Delchier JC, Bretagne JF, Courillon-Mallet A, et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003;18:791-7.
24. Zullo A, Hassan C, De Francesco V, et al. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Digestive Liver Dis 2003;35:232-6.
25. Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003;35:711-5.
26. Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM. Rescue therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003;8:90-4.
27. Roghani HS, Massarrat S, Shirekhoda M, Butorab Z. Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori. J Gastroenterol Hepatol 2003;18:778-82.
28. Ojetti V, Migneco A, Zocco MA, Nista EC, Gasbarrini G, Gasbarrini A. Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate. J Intern Med 2004;255:125-9.
29. Di Mario F, Aragona G, Bo ND, Ingegnoli A, Cavestro GM, Moussa AM, Iori V, Leandro G, Pilotto A, Franze A. Use of lactoferrin for Helicobacter pylori eradication. Preliminary result. J Clin Gastroenterol 2003;36:396-8.
30. Guttner Y, Windsor HM, Viiala CH, Marshall BJ. Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:125-9.
31. Pantoflickova D, Corthesy-Theulaz I, Dorta G, Stolte M, Isler P, Rochat F, Enslen M, Blum AL. Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment Pharmacol Ther 2003;18:805-13.
32. Ushiyama A, Tanaka K, Aiba Y, Shiba T, Takagi A, Mine T, Koga Y. Lactobacillus gassteri OLL2716 as a probiotic in clariotromycin-resistant Helicobacter pylori infection. J Gastroenterol Hepatol 2003;18:986-91.
33. Boyanova L, Derejian S, Koumanova R, Katsarov N, Gergova G, Mitov I, Nikolov R, Krastev Z. Inhibition of Helicobacter pylori growth in vitro by Bulgarian propolis: preliminary report. J Med Microbiol 2003;52:417-9.
34. Mahady GB, Pendland SL, Yun GS, Lu ZZ, Stoia A. Ginger (Zingiber officinale Roscoe) and the gingerols inhibit the growth of CagA+ strains of Helicobacter pylori. Anticancer Res 2003;23: 3699-702.
35. Ohno T, Kita M, Yamaoka Y, Imamura S, Yamamoto T, Mitsufuji S, Kodama T, Kashima K, Imanishi J. Antimicrobial activitiy of essential oils against Helicobacter pylori. Helicobacter 2003;8: 207-15.
36. Koizumi W, Tanabe S, Imaizumi H, et al. Inhibition of peptic ulcer relapse by ranitidine and ecabet independently of eradication of Helicobacter pylori: a prospective, controlled study versus ranitidine. Hepatogastroenterology 2003;50:577-81.
37. Genta RM. Review article: the role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther 2003;18:S8-S13.
38. Fujioka T, Arakawa T, Shimoyama T, et al. Effects of rebamipide, a gastro-protective drug on the Helicobacter pylori status and inflammation in the gastric mucosa of patients with gastric ulcer: a randomized double-blind placebo-controlled multicentre trial. Aliment Pharmacol Ther 2003; 18:S146-S152.
39. Higo S, Ori K, Takeuchi H, Yamamoto H, Hino T, Kawashima Y. A novel evaluation method of gastric mucoadhesive property in vitro and the mucoadhesive mechanism of tetracycline-sucralfate acidic complex for eradication of Helicobacter pylori. Pharm Res 2004;21:413-9.
40. Matsuo K, Hamajima N, Ikehara Y, Suzuki T, Nakamura T, Matsuura A, Tajima K, Tominaga S. Smoking and polymorphisms of fucosyltransferase gene Le affect success of H. pylori eradication with lansoprazole, amoxicillin, and clarithromycin. Epidemiol Infect 2003;130:227-33.